A phase 2 trial presents promising findings on the effectiveness of transdermal estradiol patches in delivering part of the androgen deprivation therapy for prostate cancer patients, showing potential in reducing adverse effects.
Data from the phase III ReNeu trial showed the kinase inhibitor led to an overall response rate of 41% in adult patients and 52% in pediatric patients.
Discover how pre-hospital blood programs are saving lives during traumatic events in both rural and urban areas, addressing crucial legal and financial barriers along the way. Source: KFF Health News.
"Non–digital rectal examination (DRE) testing provides a convenient, objective, and highly accurate testing option to reduce the need for imaging and biopsy in men with elevated [prostate-specific antigen]."